Developer docs
API playgroundTry for free, no card

Search company profiles

Connecta Therapeutics

Full company profile

uuid0000f98

Namestring
Connecta Therapeutics
Legal namestring
CONNECTA Therapeutics, S.L.
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Connecta Therapeutics is a clinical-stage biotechnology company headquartered at the Barcelona Science Park that develops disease-modifying small molecule treatments for unresolved central nervous system (CNS) disorders, with an initial focus on Fragile X Syndrome (FXS). Founded in July 2019 as a spin-off of Prous Institute for Biomedical Research, the company applies a network pharmacology platform that integrates in silico drug design with artificial intelligence techniques to identify and optimize multi-target small molecules acting on neurotrophic factor pathways. Its lead asset CTH120 is a first-in-class small molecule neuroplasticity modulator targeting the tropomyosin receptor kinase B (TrkB) receptor; preclinical studies demonstrated that CTH120 rescues dendritic pathology in FXS models, improves cognitive ability, and restores social abnormalities. A second patented compound, CTH122, has shown preclinical efficacy in both FXS and Rett syndrome models, indicating platform scalability to additional neurodevelopmental disorders.

CTH120 has received EMA Orphan Drug Designation (EU/3/21/2432, granted 2021), conferring 10-year market exclusivity in the EU upon approval and providing protocol and fee benefits during development. Connecta completed a Phase I trial in 76 healthy adults (initiated 2023, positive safety data reported March 2025) and initiated a Phase IIa randomized, double-blind, placebo-controlled multicenter study in 30 adult males aged 18–45 with FXS at Hospital del Mar Research Institute and Parc Taulí in June 2026. A pediatric development program supported by a €2.5M EIC Accelerator grant (September 2025) is underway, including formulation development for an age-appropriate oral dosage form.

The company is pre-revenue and funds operations through a mix of equity (€1.7M seed round led by Inveready in September 2020, with CDTI Innvierte and founders) and non-dilutive grants (AEI Retos-Colaboración 2019, NEOTEC 2021, ENISA participatory loan 2022, NextGenerationEU Phase IIa grant 2024, EIC Accelerator 2025). Total disclosed funding exceeds €5M. Go-to-market will follow the traditional pharmaceutical commercialization pathway through EMA approval, with orphan drug exclusivity providing the primary commercial protection in the EU. Target end users are adult and pediatric patients with FXS and, over time, patients with other neurodevelopmental disorders characterized by impaired neuroplasticity (Rett syndrome, Down syndrome, ASD, ADHD). The core team of 1–10 employees is supplemented by a strong scientific advisory board including Dr. Randi Hagerman (UC Davis MIND Institute) and Dr. Mara Dierssen (CRG).

Short descriptiontext

Connecta Therapeutics is a Barcelona-based clinical-stage biotech developing first-in-class small molecule neuroplasticity modulators, with lead asset CTH120 in Phase IIa trials for Fragile X Syndrome, targeting adult and pediatric patients with CNS disorders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBarcelona, Spain
HQ citystring
Barcelona
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CNS therapeutics, Fragile X treatment, Neuroplasticity modulators, Rare disease drugs, Orphan drug development
Industry3 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
CNS Therapeutics — Orphan Drug Development
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Revenue will be generated through commercialization of drug candidates upon regulatory approval. CTH120 targets Fragile X Syndrome, a rare disease with orphan drug designation providing 10-year market exclusivity in the EU.

connectatherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Connecta Therapeutics is a clinical-stage biotechnology company that discovers and develops AI-designed first-in-class small molecule drugs targeting neuroplasticity pathways for the treatment of central nervous system (CNS) disorders, with a primary focus on Fragile X Syndrome (FXS) and other neurodevelopmental conditions. Its lead product CTH120, a neuroplasticity modulator targeting the TrkB receptor, is advancing through Phase IIa clinical trials, with a second compound CTH122 in preclinical development for FXS and Rett syndrome.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Phase I clinical trial completed with 76 healthy adults demonstrating CTH120 was safe and well tolerated throughout the clinical trial
+2 more records
Product overview1 text field

CONNECTA Therapeutics is a clinical-stage biotech company developing a pipeline of first-in-class small molecule neuroplasticity modulators for CNS disorders. The lead product CTH120 is a novel NCE targeting TrkB receptor for Fragile X Syndrome, currently in Phase IIa clinical trials following successful Phase I completion. A second compound, CTH122, is in preclinical development with demonstrated efficacy in FXS and Rett syndrome models. Both products utilize a network pharmacology-based approach and were designed using AI techniques.

Product and service2 records
1CTH120
CategoryClinical-stage small molecule drug — CNS Therapeutics / Orphan Drug
Description

CTH120 is a first-in-class small molecule neuroplasticity modulator and the company's lead clinical asset. It is a novel new chemical entity (NCE) designed using AI techniques to target the tropomyosin receptor kinase B (TrkB) receptor for the treatment of Fragile X Syndrome (FXS). It has demonstrated preclinical efficacy in rescuing dendritic pathology, improving cognitive ability, and completely restoring social abnormalities in FXS models. It has completed Phase I safety/tolerability trials in healthy adult volunteers and is currently advancing through Phase IIa trials in adult males with FXS.

2CTH122
CategoryPreclinical small molecule drug — CNS Therapeutics
Description

CTH122 is a first-in-class small molecule with neuroplasticity modulation properties in preclinical development. It has demonstrated efficacy in preclinical models of Fragile X Syndrome and Rett syndrome. The compound is protected by a recently granted international patent family and represents a pipeline expansion asset within Connecta's network pharmacology platform.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-07-01
Description

Private research organization based in Barcelona, spin-off of Prous Science (acquired by Thomson Reuters in 2007). Founded Connecta Therapeutics in July 2019 as a spin-off. Dr. Josep Prous Jr. serves as Co-Founder and Chief Scientific Officer. Provides expertise in in silico drug discovery and safety technologies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Renowned international biomedical research centre located in Barcelona with over 400 interdisciplinary scientists. Dr. Mara Dierssen leads the Cellular and Systems Neurobiology group and serves as Research Advisor to Connecta. CRG conducted preclinical studies on CTH120 demonstrating neuroplasticity modulation and cognitive improvement. Under leadership of Mara Dierssen, CRG advances biomarker identification for FXS treatment response.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading biomedical research centre in Barcelona with around 700 professionals, among top ten Spanish institutions in scientific impact on healthcare. Dr. Rafael de la Torre serves as Principal Investigator and Study Coordinator. Conducted Phase I clinical trials and currently conducting Phase IIa clinical trial for CTH120 in adult males with FXS.

4Institute for Research and Innovation Parc Taulí (I3PT)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CERCA institute accredited by Carlos III Health Institute. Dr. Ana Roche serves as Principal Investigator. Joined Phase IIa clinical trial as strategic partner alongside CRG and Hospital del Mar Research Institute. Conducts clinical research in neurodevelopmental disorders.

connectatherapeutics.com
5Dr. Randi Hagerman (UC Davis MIND Institute)
Strategic tierMinorTypeOthers
Description

Internationally recognized clinician and researcher in fragile X field. Serves as Clinical Advisor and Medical Director at UC Davis MIND Institute. Distinguished Professor and Endowed Chair in Fragile X Research. Has carried out multiple targeted treatment trials in FXS and autism.

connectatherapeutics.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech that developed Zygel (CBD gel) for Fragile X Syndrome and other neurodevelopmental disorders — the most direct historical competitor in FXS drug development. Highly comparable target indication and patient population, providing direct read-throughs on FXS clinical trial design and commercial viability.

TypeDirect peer
Description

CNS-focused biotech developing therapeutics for rare neurodevelopmental disorders including Fragile X Syndrome and Angelman syndrome. Directly comparable in indication focus (FXS), pipeline stage, and strategy of orphan-designated CNS small molecules.

TypeDirect peer
Description

Specialty pharma developing CNS therapies for rare epilepsies and neurodevelopmental disorders (e.g., CDKL5 deficiency disorder). Comparable as a small-cap CNS rare-disease company pursuing orphan indications with similar regulatory and clinical-development profiles.

TypeBroad incumbent
Description

Acquired by Jazz Pharmaceuticals, GW developed Epidiolex (cannabidiol) — approved for seizures associated with FXS-related conditions such as Dravet and Lennox-Gastaut syndromes. Comparable as a CNS specialty company that has reached FDA approval in FXS-adjacent indications, representing both an incumbent and an aspirational benchmark.

TypeBroad incumbent
Description

CNS specialty biopharma developing first-in-class neuroactive therapeutics (e.g., Zurzuvae). Comparable as an established CNS specialty player pursuing novel mechanisms for underserved neurological indications, providing a model for Connecta's potential commercial trajectory.

TypeBroad incumbent
Description

Commercial-stage CNS specialty pharma (e.g., Nuplazid for Parkinson's psychosis, DAYBUE for Rett syndrome). Highly relevant peer given DAYBUE's approval for Rett syndrome — an explicit expansion indication in Connecta's CTH122 preclinical portfolio.

TypeBroad incumbent
Description

CNS-focused specialty pharma with FDA-approved products for major depressive disorder and migraine. Comparable as a CNS-specialist commercial-stage company, illustrating the scaling pathway available to Connecta if CTH120 reaches approval.

TypeEmerging player
Description

Clinical-stage biotech developing CNS therapeutics for Rett syndrome, Alzheimer's, and Parkinson's disease. Comparable as a small-cap CNS developer pursuing neurodevelopmental and neurodegenerative indications with novel mechanisms.

TypeEmerging player
Description

European-based CNS specialty biopharma developing treatments for rare neurological and neuropsychiatric disorders. Comparable as a EU-headquartered CNS specialty company with a similar scale and orphan-disease strategy.

TypeEmerging player
Description

Clinical-stage biotech developing CNS therapies for neuropsychiatric and neurodevelopmental conditions. Comparable as a small-cap CNS developer focused on underserved neurological indications, although at a generally earlier development stage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Connecta Therapeutics

CNS Therapeutics — Orphan Drug Developmentconnectatherapeutics.com

Connecta Therapeutics is a Barcelona-based clinical-stage biotech developing first-in-class small molecule neuroplasticity modulators, with lead asset CTH120 in Phase IIa trials for Fragile X Syndrome, targeting adult and pediatric patients with CNS disorders.

What Connecta Therapeutics does

Connecta Therapeutics is a clinical-stage biotechnology company headquartered at the Barcelona Science Park that develops disease-modifying small molecule treatments for unresolved central nervous system (CNS) disorders, with an initial focus on Fragile X Syndrome (FXS). Founded in July 2019 as a spin-off of Prous Institute for Biomedical Research, the company applies a network pharmacology platform that integrates in silico drug design with artificial intelligence techniques to identify and optimize multi-target small molecules acting on neurotrophic factor pathways. Its lead asset CTH120 is a first-in-class small molecule neuroplasticity modulator targeting the tropomyosin receptor kinase B (TrkB) receptor; preclinical studies demonstrated that CTH120 rescues dendritic pathology in FXS models, improves cognitive ability, and restores social abnormalities. A second patented compound, CTH122, has shown preclinical efficacy in both FXS and Rett syndrome models, indicating platform scalability to additional neurodevelopmental disorders.

CTH120 has received EMA Orphan Drug Designation (EU/3/21/2432, granted 2021), conferring 10-year market exclusivity in the EU upon approval and providing protocol and fee benefits during development. Connecta completed a Phase I trial in 76 healthy adults (initiated 2023, positive safety data reported March 2025) and initiated a Phase IIa randomized, double-blind, placebo-controlled multicenter study in 30 adult males aged 18–45 with FXS at Hospital del Mar Research Institute and Parc Taulí in June 2026. A pediatric development program supported by a €2.5M EIC Accelerator grant (September 2025) is underway, including formulation development for an age-appropriate oral dosage form.

The company is pre-revenue and funds operations through a mix of equity (€1.7M seed round led by Inveready in September 2020, with CDTI Innvierte and founders) and non-dilutive grants (AEI Retos-Colaboración 2019, NEOTEC 2021, ENISA participatory loan 2022, NextGenerationEU Phase IIa grant 2024, EIC Accelerator 2025). Total disclosed funding exceeds €5M. Go-to-market will follow the traditional pharmaceutical commercialization pathway through EMA approval, with orphan drug exclusivity providing the primary commercial protection in the EU. Target end users are adult and pediatric patients with FXS and, over time, patients with other neurodevelopmental disorders characterized by impaired neuroplasticity (Rett syndrome, Down syndrome, ASD, ADHD). The core team of 1–10 employees is supplemented by a strong scientific advisory board including Dr. Randi Hagerman (UC Davis MIND Institute) and Dr. Mara Dierssen (CRG).

Connecta Therapeutics firmographics

Firmographics
Name
Connecta Therapeutics
Legal name
CONNECTA Therapeutics, S.L.
Website
https://connectatherapeutics.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Connecta Therapeutics is a Barcelona-based clinical-stage biotech developing first-in-class small molecule neuroplasticity modulators, with lead asset CTH120 in Phase IIa trials for Fragile X Syndrome, targeting adult and pediatric patients with CNS disorders.
Ownership category
akta.pro rank

Connecta Therapeutics industry classification

Industry
Product category
CNS Therapeutics — Orphan Drug Development
NAICS
Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAAAMAD
Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAAAIAK
In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • CNS therapeutics
  • Fragile X treatment
  • Neuroplasticity modulators
  • Rare disease drugs
  • Orphan drug development

Where Connecta Therapeutics is headquartered

Location

Headquarters

HQ city
Barcelona
HQ country
Spain
HQ region
Europe

Offices1 record

Markets served

Connecta Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pharmaceutical Development and Commercialization: Pre-revenue clinical-stage biotech company. Revenue will be generated through commercialization of drug candidates upon regulatory approval. CTH120 targets Fragile X Syndrome, a rare disease with orphan drug designation providing 10-year market exclusivity in the EU.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Connecta Therapeutics product offering

Product offering

Core offering

Connecta Therapeutics is a clinical-stage biotechnology company that discovers and develops AI-designed first-in-class small molecule drugs targeting neuroplasticity pathways for the treatment of central nervous system (CNS) disorders, with a primary focus on Fragile X Syndrome (FXS) and other neurodevelopmental conditions. Its lead product CTH120, a neuroplasticity modulator targeting the TrkB receptor, is advancing through Phase IIa clinical trials, with a second compound CTH122 in preclinical development for FXS and Rett syndrome.

Product overview

CONNECTA Therapeutics is a clinical-stage biotech company developing a pipeline of first-in-class small molecule neuroplasticity modulators for CNS disorders. The lead product CTH120 is a novel NCE targeting TrkB receptor for Fragile X Syndrome, currently in Phase IIa clinical trials following successful Phase I completion. A second compound, CTH122, is in preclinical development with demonstrated efficacy in FXS and Rett syndrome models. Both products utilize a network pharmacology-based approach and were designed using AI techniques.

Differentiator

Problem solved

Functional benefit

Products and services

  • CTH120 CTH120 is a first-in-class small molecule neuroplasticity modulator and the company's lead clinical asset. It is a novel new chemical entity (NCE) designed using AI techniques to target the tropomyosin receptor kinase B (TrkB) receptor for the treatment of Fragile X Syndrome (FXS). It has demonstrated preclinical efficacy in rescuing dendritic pathology, improving cognitive ability, and completely restoring social abnormalities in FXS models. It has completed Phase I safety/tolerability trials in healthy adult volunteers and is currently advancing through Phase IIa trials in adult males with FXS.
  • CTH122 CTH122 is a first-in-class small molecule with neuroplasticity modulation properties in preclinical development. It has demonstrated efficacy in preclinical models of Fragile X Syndrome and Rett syndrome. The compound is protected by a recently granted international patent family and represents a pipeline expansion asset within Connecta's network pharmacology platform.

Quantifiable outcome

  • Phase I clinical trial completed with 76 healthy adults demonstrating CTH120 was safe and well tolerated throughout the clinical trial
  • +2 more outcomes

Companies that use Connecta Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Connecta Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Connecta Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Prous Institute for Biomedical ResearchcoreStrategic or Co-development Partner · 1 July 2019Private research organization based in Barcelona, spin-off of Prous Science (acquired by Thomson Reuters in 2007). Founded Connecta Therapeutics in July 2019 as a spin-off. Dr. Josep Prous Jr. serves as Co-Founder and Chief Scientific Officer. Provides expertise in in silico drug discovery and safety technologies.
  • Centre for Genomic Regulation (CRG)coreStrategic or Co-development PartnerRenowned international biomedical research centre located in Barcelona with over 400 interdisciplinary scientists. Dr. Mara Dierssen leads the Cellular and Systems Neurobiology group and serves as Research Advisor to Connecta. CRG conducted preclinical studies on CTH120 demonstrating neuroplasticity modulation and cognitive improvement. Under leadership of Mara Dierssen, CRG advances biomarker identification for FXS treatment response.
  • Hospital del Mar Research Institute (HMRIB)coreStrategic or Co-development PartnerLeading biomedical research centre in Barcelona with around 700 professionals, among top ten Spanish institutions in scientific impact on healthcare. Dr. Rafael de la Torre serves as Principal Investigator and Study Coordinator. Conducted Phase I clinical trials and currently conducting Phase IIa clinical trial for CTH120 in adult males with FXS.
  • Institute for Research and Innovation Parc Taulí (I3PT)coreStrategic or Co-development PartnerCERCA institute accredited by Carlos III Health Institute. Dr. Ana Roche serves as Principal Investigator. Joined Phase IIa clinical trial as strategic partner alongside CRG and Hospital del Mar Research Institute. Conducts clinical research in neurodevelopmental disorders.
  • Dr. Randi Hagerman (UC Davis MIND Institute)minorOthersInternationally recognized clinician and researcher in fragile X field. Serves as Clinical Advisor and Medical Director at UC Davis MIND Institute. Distinguished Professor and Endowed Chair in Fragile X Research. Has carried out multiple targeted treatment trials in FXS and autism.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Connecta Therapeutics competitors and assessment

Company assessment

Direct peers

  • Zynerba Pharmaceuticals: Clinical-stage biotech that developed Zygel (CBD gel) for Fragile X Syndrome and other neurodevelopmental disorders — the most direct historical competitor in FXS drug development. Highly comparable target indication and patient population, providing direct read-throughs on FXS clinical trial design and commercial viability.
  • Ovid Therapeutics: CNS-focused biotech developing therapeutics for rare neurodevelopmental disorders including Fragile X Syndrome and Angelman syndrome. Directly comparable in indication focus (FXS), pipeline stage, and strategy of orphan-designated CNS small molecules.
  • Marinus Pharmaceuticals: Specialty pharma developing CNS therapies for rare epilepsies and neurodevelopmental disorders (e.g., CDKL5 deficiency disorder). Comparable as a small-cap CNS rare-disease company pursuing orphan indications with similar regulatory and clinical-development profiles.

Broad incumbents

  • GW Pharmaceuticals (Jazz Pharmaceuticals): Acquired by Jazz Pharmaceuticals, GW developed Epidiolex (cannabidiol) — approved for seizures associated with FXS-related conditions such as Dravet and Lennox-Gastaut syndromes. Comparable as a CNS specialty company that has reached FDA approval in FXS-adjacent indications, representing both an incumbent and an aspirational benchmark.
  • Sage Therapeutics: CNS specialty biopharma developing first-in-class neuroactive therapeutics (e.g., Zurzuvae). Comparable as an established CNS specialty player pursuing novel mechanisms for underserved neurological indications, providing a model for Connecta's potential commercial trajectory.
  • Acadia Pharmaceuticals: Commercial-stage CNS specialty pharma (e.g., Nuplazid for Parkinson's psychosis, DAYBUE for Rett syndrome). Highly relevant peer given DAYBUE's approval for Rett syndrome — an explicit expansion indication in Connecta's CTH122 preclinical portfolio.
  • Axsome Therapeutics: CNS-focused specialty pharma with FDA-approved products for major depressive disorder and migraine. Comparable as a CNS-specialist commercial-stage company, illustrating the scaling pathway available to Connecta if CTH120 reaches approval.

Emerging players

  • Anavex Life Sciences: Clinical-stage biotech developing CNS therapeutics for Rett syndrome, Alzheimer's, and Parkinson's disease. Comparable as a small-cap CNS developer pursuing neurodevelopmental and neurodegenerative indications with novel mechanisms.
  • Newron Pharmaceuticals: European-based CNS specialty biopharma developing treatments for rare neurological and neuropsychiatric disorders. Comparable as a EU-headquartered CNS specialty company with a similar scale and orphan-disease strategy.
  • Pasithea Therapeutics: Clinical-stage biotech developing CNS therapies for neuropsychiatric and neurodevelopmental conditions. Comparable as a small-cap CNS developer focused on underserved neurological indications, although at a generally earlier development stage.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Connecta Therapeutics social profiles

Digital presence

Connecta Therapeutics compliance and trust

Trust signal

Compliance1 record

Connecta Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Connecta Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Connecta Therapeutics funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Connecta Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Connecta Therapeutics

What does Connecta Therapeutics do?

Connecta Therapeutics is a clinical-stage biotechnology company that discovers and develops AI-designed first-in-class small molecule drugs targeting neuroplasticity pathways for the treatment of central nervous system (CNS) disorders, with a primary focus on Fragile X Syndrome (FXS) and other neurodevelopmental conditions. Its lead product CTH120, a neuroplasticity modulator targeting the TrkB receptor, is advancing through Phase IIa clinical trials, with a second compound CTH122 in preclinical development for FXS and Rett syndrome.

Is Connecta Therapeutics a public or private company?

Connecta Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Connecta Therapeutics founded?

Connecta Therapeutics was founded in 2019. It employs 1 to 10 people.

Where is Connecta Therapeutics based?

Connecta Therapeutics is headquartered in Barcelona, Spain, in the Europe region.

How does Connecta Therapeutics make money?

One revenue line is on record: pharmaceutical Development and Commercialization.

Who are Connecta Therapeutics's main competitors?

Direct peers on record are Zynerba Pharmaceuticals, Ovid Therapeutics and Marinus Pharmaceuticals. Broad incumbents are GW Pharmaceuticals (Jazz Pharmaceuticals), Sage Therapeutics, Acadia Pharmaceuticals and Axsome Therapeutics. Emerging players are Anavex Life Sciences, Newron Pharmaceuticals and Pasithea Therapeutics.

Does Connecta Therapeutics have an API?

No public API is recorded for Connecta Therapeutics.

What industry is Connecta Therapeutics in?

Connecta Therapeutics's product category is CNS Therapeutics — Orphan Drug Development. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAAAMAD, Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
El ReferenteCONNECTA Therapeutics levanta 3,1 millones de eurosCONNECTA Therapeutics raised €3.1 million to advance its first-in-class neuroplasticity modulator CTH120 for fragile X syndrome. The funds will support the Phase IIa trial in 30 adult males, with data expected in mid-2027. The company is also preparing pediatric development under FRAXCURE.El ReferenteCONNECTA Therapeutics levanta 3,1 millones de eurosCONNECTA Therapeutics raised €3.1 million to advance its first-in-class neuroplasticity modulator CTH120 for fragile X syndrome. The funds will support the Phase IIa trial in 30 adult males, with data expected in mid-2027. The company is also preparing pediatric development under FRAXCURE.El ReferenteCONNECTA Therapeutics levanta 3,1 millones de eurosCONNECTA Therapeutics raised €3.1 million to advance its first-in-class neuroplasticity modulator CTH120 for fragile X syndrome. The funds will support the Phase IIa trial in 30 adult males, with data expected in mid-2027. The company is also preparing pediatric development under FRAXCURE.El ReferenteCONNECTA Therapeutics levanta 3,1 millones de eurosCONNECTA Therapeutics raised €3.1 million to advance its first-in-class neuroplasticity modulator CTH120 for fragile X syndrome. The funds will support the Phase IIa trial in 30 adult males, with data expected in mid-2027. The company is also preparing pediatric development under FRAXCURE.FinSMEsConnecta Therapeutics Raises €3.1M in FundingConnecta Therapeutics, a Barcelona-based biotech, raised €3.1M in funding led by Clave Capital. The company will use the funds to expand operations and development efforts, with its lead program CTH120 targeting Fragile X syndrome.WebcapitalriesgoCONNECTA Therapeutics (síndrome X Frágil) atrae €3,1M en ronda liderada por Clave. Participa Inveready, CDTI y Prous InstituteCONNECTA Therapeutics closed a €3.1M funding round led by Clave Capital, with participation from Inveready, CDTI, and Prous Institute. The funds will support the Phase IIa trial of CTH120 in fragile X syndrome, with preliminary results expected in mid-2027.BioSpaceCONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Syndrome ProgramCONNECTA Therapeutics closed €3.1 million financing led by Clave Capital to advance its CTH120 program for Fragile X syndrome. The funds will support the Phase IIa trial of CTH120 in adult males, with topline data expected in mid-2027. The company is also preparing for pediatric development under the FRAXCURE project.ConnectatherapeuticsCONNECTA Therapeutics Announces Financing to Advance Clinical Development of Fragile X Syndrome Program – CONNECTA TherapeuticsCONNECTA Therapeutics closed a €3.1 million financing led by Clave Capital to advance its Fragile X syndrome program. The funds will support the Phase IIa trial of CTH120 in adult males, with topline data expected in mid-2027. The company is also preparing for pediatric development under the FRAXCURE project.European BiotechnologyConnecta raises €3.1M for Fragile X syndrome Phase 2Connecta raised €3.1M to complete a 30-patient Phase 2a study of its Fragile X candidate CTH120, with first efficacy data expected in mid-2027. The study tests 75 mg twice daily against placebo, following a safe Phase 1 trial. The company is also preparing a pediatric study.Empresas de Capital Riesgo en EspaCONNECTA Therapeutics raises €3.1 million in a round led by Clave to advance the clinical development of its Fragile X syndrome programmeCONNECTA Therapeutics closed a €3.1 million financing round led by Clave Capital to advance its Fragile X syndrome programme. The funds will support Phase IIa clinical development of CTH120 in adult males, with data expected in mid-2027. The company is also preparing paediatric development under the FRAXCURE project.